The obesity treatment landscape just shifted in a way that matters for anyone following oral GLP-1 development. Foundayo - Eli Lilly’s orforglipron pill - has become the first oral GLP-1 receptor agonist to receive FDA approval, and it’s now one of three drugs included in the US Medicare system’s new GLP-1 Bridge Program launching on 1 July 2026.
What Is Foundayo?
Orforglipron is a small-molecule GLP-1 receptor agonist - meaning it activates the same GLP-1 receptor as semaglutide and tirzepatide, but it’s not a peptide. It’s a synthetic small molecule that can survive the digestive system without being broken down, which is the main challenge that has kept injectable peptides as the dominant delivery method for GLP-1 drugs.
The FDA approved Foundayo in April 2026 based on Phase 3 trial data showing meaningful weight loss in participants with obesity. Eli Lilly has been positioning it as a complement to its injectable portfolio - Mounjaro (tirzepatide) for those who don’t mind needles, and Foundayo for those who prefer a pill.
The Medicare Bridge Program
Starting 1 July 2026, the US Medicare system will offer three GLP-1 weight-loss medications to eligible beneficiaries for $50 per month: Wegovy (semaglutide, Novo Nordisk), Zepbound (tirzepatide, Eli Lilly), and Foundayo (orforglipron, Eli Lilly).
The program is designed as a temporary bridge while longer-term pricing and coverage policies are finalised. But the inclusion of an oral GLP-1 alongside two established injectables signals that the US government sees needle-free options as part of the future of obesity treatment.
Up to 14 million Medicare patients could be eligible for the program, which represents the largest expansion of GLP-1 access in US history.
Why This Matters for Oral GLP-1 Research
The approval of Foundayo validates a research direction that many in the peptide community have been watching closely. The challenge of creating an oral GLP-1 that actually works has been one of the biggest problems in pharmaceutical chemistry. Peptides are broken down by stomach acid and digestive enzymes, which is why semaglutide and tirzepatide require injection.
The solutions fall into two categories:
Small-molecule agonists like orforglipron - these are non-peptide drugs that activate the GLP-1 receptor through a different chemical mechanism. They’re structurally different from peptide-based drugs but produce similar effects. Foundayo falls into this category.
Oral peptide formulations with absorption enhancers - these use the actual peptide molecule but protect it during digestion. Oral semaglutide (Rybelsus) uses this approach with a sodium caprate absorption enhancer. Corxel’s CX11 and AstraZeneca’s elecoglipron are pursuing similar strategies.
Foundayo’s approval shows that the small-molecule approach can work at scale. The Phase 3 data showed weight loss comparable to early GLP-1 injectables, though not yet matching the newer dual-agonist compounds like tirzepatide.
What the Research Says
The clinical trial data for orforglipron showed:
- Statistically significant weight loss compared to placebo
- A safety profile consistent with the GLP-1 class (gastrointestinal side effects being the most common)
- Once-daily oral dosing, which is a significant convenience advantage over injectables
The weight loss numbers were lower than what tirzepatide has shown in its trials, which is expected given that tirzepatide activates both GLP-1 and GIP receptors while orforglipron targets only GLP-1. But for people who won’t or can’t use injectables, the oral option represents a meaningful alternative.
Eli Lilly is also launching Foundayo in Europe through direct sales before seeking public healthcare reimbursement, signalling confidence in the product’s commercial potential.
The Australian Angle
For the Australian research community, the development of effective oral GLP-1 compounds is relevant for several reasons. The TGA’s regulatory approach to these drugs differs from the FDA’s, and access timelines are typically longer. But the global trend toward oral obesity treatments is accelerating, and the competitive pressure between injectable and oral options is likely to benefit consumers in the long run.
The existing oral GLP-1 landscape includes Rybelsus (oral semaglutide, already available in Australia for type 2 diabetes), with several other candidates in late-stage development. Foundayo’s US approval adds another option to the mix and may influence TGA consideration timelines.
We’ll be keeping an eye on how the Australian regulatory pathway develops for orforglipron and other oral GLP-1 candidates. Check our GLP-1 weight loss science page for more on how these compounds work.
Sources
Source: How To Get Orforglipron Online (Forbes, 30 June 2026)
Source: Up to 14M Medicare patients could be eligible for GLP-1s for just $50 a month (Yahoo Finance, 19 June 2026)
Source: Eli Lilly Is Taking America’s Weight-Loss Drug Playbook to Europe With New Obesity Pill (International Business Times, 24 June 2026)
Source: Is Bariatric Surgery Over? (Medscape, 26 June 2026)
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.